Alx Oncology Holdings (ALXO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alx Oncology Holdings (ALXO) has a cash flow conversion efficiency ratio of -0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.65 Million) by net assets ($151.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Alx Oncology Holdings 's balance sheet to measure how much of total assets are equity-financed.
Alx Oncology Holdings - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ALXO long-term investments to assets to see how much of total assets are deployed in long-term investments.
Alx Oncology Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alx Oncology Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Supermax Corporation Bhd
KLSE:7106
|
0.001x |
|
Suzhou Harmontronics Auto Tech Co Ltd
SHG:688022
|
-0.032x |
|
Seoyon E Hwa Co Ltd
KO:200880
|
0.017x |
|
Yantai Changyu Pioneer Wine
SHE:200869
|
0.012x |
|
Insecticides (India) Limited
NSE:INSECTICID
|
-0.101x |
|
Brogent Technologies
TWO:5263
|
0.031x |
|
HMS Bergbau AG
XETRA:HMU
|
-0.399x |
|
BVZ Holding AG
SW:BVZN
|
0.079x |
Annual Cash Flow Conversion Efficiency for Alx Oncology Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Alx Oncology Holdings from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ALXO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $25.98 Million | $-84.14 Million | -3.239x | -201.83% |
| 2024-12-31 | $113.62 Million | $-121.91 Million | -1.073x | -56.15% |
| 2023-12-31 | $189.71 Million | $-130.36 Million | -0.687x | -102.91% |
| 2022-12-31 | $263.46 Million | $-89.22 Million | -0.339x | -80.54% |
| 2021-12-31 | $363.05 Million | $-68.10 Million | -0.188x | -110.58% |
| 2020-12-31 | $429.85 Million | $-38.29 Million | -0.089x | -100.17% |
| 2019-12-31 | $-276.00K | $-14.25 Million | 51.627x | +3683.35% |
| 2018-12-31 | $9.15 Million | $-13.19 Million | -1.441x | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more